… Susan Dent MD … Susan Dent MD … DISCLOSURES: Susan Dent reports consulting fees
from Hoffman-La Roche, Novartis, and Amgen outside the submitted work. Daniel Lenihan reports …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified that,
unless otherwise provided for by national regulations, offlabel use of medication should be …

… Armenian, Christina Lacchetti, Ana Barac, Joseph Carver, Louis Sandy Constine,
Neelima Denduluri, Susan Dent, Pamela S. Douglas, Jean-Bernard Durand, Michael Ewer …

This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio‐Oncology …

Purpose Most women with breast cancer are diagnosed at an early stage and more than 80%
will be long-term survivors. Routine follow-up marks the transition from intensive treatment …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in …

In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is
devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and …

Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women’s health. CVD and …